研究助理教授 (副研究员) 格拉布斯研究院 课题组网站
周启璠,浙江台州人,现任南方科技大学格拉布斯研究院研究助理教授(副研究员),生物技术副高级工程师。2019年于沈阳药科大学获得药物化学专业博士学位,师从陈国良教授,并荣获国家奖学金。主要从事肿瘤、病毒和炎症相关疾病的小分子创新药物研究与开发。于2020年加入南方科技大学张绪穆教授课题组,作为项目骨干完成新型口服抗新冠药物SHEN26的临床前研究工作,目前已完成III期临床试验进入上市申请阶段。以一作或共一作在STM, STTT, EJMC, JOC等期刊发表SCI文章20余篇,申请发明专利20余项,其中作为主要发明人获得中国专利授权9项。
个人简介
个人简介
研究领域
1. 基于病毒共性靶标的小分子药物开发;
2. 发展基于新机制、新靶点的抗肿瘤、抗炎和抗病毒小分子抑制剂
学术成果 查看更多
- Qishu Chen1, Qifan Zhou1, Guanguan Li, Shuo Li, Yingjun Li* and Xumu Zhang*. Optimized kilogram-scale synthesis and impurity identification of SHEN26 (ATV014) for treating COVID-19. Organic Process Research & Development. 2023, doi.org/10.1021/acs.oprd.3c00248. (IF: 3.1)
- Qifan Zhou1, Sidi Yang1, Liu Cao1, Yang Yang1, Tiefeng Xu, Qishu Chen, Hongzhou Lu, Yingjun Li*, Deyin Guo*, Xumu Zhang*. Preclinical characterization of SHEN26, an oral cyclohexanecarboxylate prodrug of 1′-CN-4-aza-7,9-dideazaadenosine C-nucleoside for the treatment of SARS-CoV-2. Signal Transduction and Targeted Therapy, 2023, 8, 27. (IF: 40.8)
- Qifan Zhou1, Yinzhu Luo1, Yujun Zhu1, Qishu Chen, Jingfei Qiu, Feng Cong*, Yingjun Li*, Xumu Zhang*. Nonsteroidal anti-inflammatory drugs (NSAIDs) and nucleotide analog GS-441524 conjugates with potent in vivo efficacy against coronaviruses. European Journal of Medicinal Chemistry, 2023, 249, (IF = 6.0)
- Liu Cao1, Yingjun Li1, Sidi Yang1, Guanguan Li1, Qifan Zhou1, Jing Sun1, et al. The adenosine analogue prodrug ATV006 is orally bioavailable and has potent preclinical efficacy against SARS-CoV-2 and its variants. Science Translational Medicine, 2022, 14, eabm7621. (Co-author, IF=15.8)
- Qifan Zhou, Lina Jia, Fangyu Du, Xiaoyu Dong, Wanyu Sun, Lihui Wang, Guoliang Chen*. Design, synthesis and biological activities of pyrrole-3-carboxamide derivatives as EZH2 (enhancer of zeste homologue 2) inhibitors and anticancer agents. New Journal of Chemistry, 2020, 44, 2247-2255. (IF = 925)
- Fangyu Du1, Qifan Zhou1, Wenjiao Sun, Cheng Yang, Chunfu Wu, Lihui Wang* and Guoliang Chen*. 5-Hydroxyindole-based EZH2 inhibitors assembled via TCCA-catalyzed condensation and Nenitzescu reactions. Molecules, 2020, 25, 2059–2083. (IF = 927)
- Qifan Zhou, Fangyu Du, Yuanguang Chen, Yang Fu, Wenjiao Sun, Ying Wu, Guoliang Chen*. L-(-)-Quebrachitol as a ligand for selective copper (0)-catalyzed N‑arylation of nitrogen-containing heterocycles. Journal of Organic Chemistry, 2019, 84, 8160–8167. (IF = 198)
- Qifan Zhou, Fangyu Du, Yuanguang Chen, Yang Fu, Guoliang Chen*. “On Water” promoted N-arylation reactions using Cu (0)/myo-inositol catalytic system. Tetrahedron Letters, 2019, 60, 1938–1941. (IF =032)
- Chunling Yuan1, Xiaoli Guo1, Qifan Zhou1, Fangyu Du, Xiaoyu Zhou, Peng Liu, Tianyan Chi, Xuefei Ji, Jinheng Gao, Chengwen Chen, Hongli Lang, Jia Xu, Danyang Liu, Yang Yang, Shimeng Qiu, Guoliang Chen* and Libo Zou*. OAB-14, a novel small molecule, improves Alzheimer’s disease-related pathologies and cognitive impairments by increasing
-amyloid clearance in APP/PS1 mice. BBA-Molecular Basis of Disease, 2019, 1865, 161–180. (IF = 633) - Yajie Shi1, Qifan Zhou1, Fangyu Du, Yang Fu, Yang Du, Ting Fang and Guoliang Chen*. Iridium-catalyzed intramolecular C-N and C-O/S cross-coupling reactions: Preparation of benzoazole derivatives. Tetrahedron Letters, 2019, 60, 151082–151090. (IF = 032)
- Fangyu Du1, Qifan Zhou1, Yang Fu, Yuanguang Chen, Ying Wu* and Guoliang Chen*. Copper(II)-catalyzed C–N coupling of aryl halides and N-nucleophiles promoted by quebrachitol or diethylene glycol. Synlett, 2019, 30, 2161–2168. (IF =170)
- Fangyu Du1, Qifan Zhou1, Yang Fu, Hanqi Zhao, Yuanguang Chen and Guoliang Chen*. tert-Butyl(3-cyano-4,6-dimethylpyridin-2-yl)carbonate as a green and chemoselective N–tert-butoxycarbonylation reagent. New Journal of Chemistry, 2019, 43, 6549–6554. (IF = 925)
- Fangyu Du, Qifan Zhou, Xiaoxiao Fu, Yajie Shi, Yuanguang Chen, Wuhong Fang, Jingyu Yang* and Guoliang Chen*. Synthesis and biological evaluation of 2,2-dimethylbenzopyran derivatives as potent neuroprotection agents. RSC Advances, 2019, 9, 2498–2508. (IF = 036)
- Fangyu Du, Qifan Zhou, Wenjiao Sun and Guoliang Chen*. Targeting cancer stem cells in drug discovery: Current state and future perspectives. World Journal of Stem Cells, 2019, 11, 398–420. (IF = 247)
- Fangyu Du, Qifan Zhou, Yajie Shi, Miao Yu, Wenjiao Sun and Guoliang Chen*. Synthesis of regorafenib through novel preparation of the intermediate 4-amino-3-fluorophenol via fries and Beckman rearrangements. Synthetic Communications, 2019, 49, 576–586. (IF =937)
- Caijiao Wu1, Qifan Zhou1, Dake Song, Hui Li, Changshun Bao, Xuelong Liu, Xuefei Bao and Guoliang Chen*. An improved process for the preparation of pimavanserin tartrate. Journal of Chemical Research, 2019, 43, 480-485. (IF =097)
- Qifan Zhou, Chen Peng, Fangyu Du, Linbo Zhou, Yajie Shi, Yang Du, Dongdong Liu, Wenjiao Sun, Meixia Zhang*, Guoliang Chen*. Design, synthesis and activity of BBI608 derivatives targeting on stem cells. European Journal of Medicinal Chemistry, 2018, 151, 39-50. (IF =0)
- Qifan Zhou, Fangyu Du, Xinjie Liang, Wenqiang Liu, Ting Fang and Guoliang Chen*. Zinc (II)-mediated selective O-benzylation of 2-oxo-1,2-dihydropyridines systems. Molecules, 2018, 23, 1784-1798. (IF = 927)
- Qifan Zhou, Fangyu Du, Yajie Shi, Wenqiang Liu, Dongdong Liu and Guoliang Chen*. An efficient protocol for the production of pymetrozine via a new synthetic strategy. Journal of Chemical Research, 2018, 42, 395-446. (IF =097)
- Qifan Zhou, Fangyu Du, Yajie Shi, Ting Fang, Guoliang Chen*. The synthesis and analysis of 1-methyl-4-phenyl-1H-imidazol-2-amine and by-products. Journal of Chemical Research, 2018, 42, 608–610. (IF =097)
- Fangyu Du, Qifan Zhou, Dongdong Liu, Ting Fang, Yajie Shi, Yang Du, Guoliang Chen*. Dimerization of aromatic compounds using palladium-carbon catalyzed Suzuki–Miyaura cross-coupling by one-pot synthesis. Synlett, 2018, 29, 779-784. (IF =170)